arrow
O

Odile Boespflug-Tanguy

hopital robert debre
H指数:56
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Death following high-dose AAV9 gene therapy in a patient with advanced SMA-PME

高级脊髓性肌萎缩症-肌阵挛性癫痫(SMA-PME)患者接受高剂量AAV9基因疗法后死亡

2026-05-260
OAAI
Restorative macrophage-derived RNAseT2 stimulates muscle stem cell fusion via an SLK/N-WASP/actin bundling dependent axis

修复性巨噬细胞衍生的RNAseT2通过SLK/N-WASP/肌动蛋白束依赖轴刺激肌肉干细胞融合

2026-04-140
OA
Dominant and recessive ATOH1 variants cause distinct neurodevelopmental disorders with hearing loss
2026-01-260
PRE
ARSA Variants Associated With Cognitive Decline and Long-Term Preservation of Motor Function in Metachromatic Leukodystrophy

ARSA变体与认知能力下降及异染性脑白质营养不良中运动功能的长期维持相关

2025-08-020
OA
Acid Ceramidase Deficiency
2025-04-010
PRE
Triheptanoin Did Not Show Benefit versus Placebo for the Treatment of Paroxysmal Movement Disorders in Glut1 Deficiency Syndrome: Results of a Randomized Phase 3 Study
2024-05-094
OA
Sunfish parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)

翻车鱼第1部分和第2部分: risdipram在2型和3型脊髓性肌萎缩症 (SMA) 中的4年疗效和安全性数据

2023-12-010
PRE
Titin copy number variations associated with dominant inherited phenotypes
2023-11-070
OA
RINT1 deficiency disrupts lipid metabolism and underlies a complex hereditary spastic paraplegia
2023-07-174
OAAI
Prospective Multicenter Validation of a Simple Blood Test for the Diagnosis of Glut1 Deficiency Syndrome
2023-06-066
OAAI
FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam in Type 1 spinal muscular atrophy (SMA)

萤火虫第1部分和第2部分: risdipram在1型脊髓性肌萎缩症 (SMA) 中的36个月安全性和有效性

2023-04-251
PRE
Bi-allelic loss-of-function variants in TMEM147 cause moderate to profound intellectual disability with facial dysmorphism and pseudo-Pelger-Huet anomaly
2022-10-017
OAAI